Announcements
For information about NCI SBIR & STTR Funding Opportunities and other announcements, please see below:
SBIR Grant Funding Opportunities:
PA-09-187, Technology Development for the Detection and Evaluation of Chemical and Biological Carcinogens (SBIR) [R43/R44]
Receipt Dates: April 5; August 5; December 5, 2009
PA-09-188, Technologies and Software to Support Integrative Cancer Biology Research (SBIR) [R43/R44]
Receipt Dates: April 5; August 5; December 5, 2009
PA-09-189, Technology for the Detection and Characterization of Low Abundance Proteins, Peptides, or micro RNAs (SBIR) [R43/R44]
Receipt Dates: April 5; August 5; December 5, 2009
PA-09-080, PHS 2009-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
Receipt Dates: April 5; August 5; December 5, 2009
STTR Grant Funding Opportunities:
PA-08-081, PHS 2009-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
Receipt Dates: April 5; August 5; December 5, 2009
Notices:
SBIR Phase II Bridge Awardees Announced
The National Cancer Institute’s (NCI) Small Business Innovation Research Program (SBIR) is pleased to announce the awarding of its first two Phase II Bridge Awards, a new funding opportunity for promising cancer therapies and imaging technologies that more than triples the amount of funding available through the NCI SBIR Program.
The first two companies to receive the Phase II Bridge Awards are:
- Lpath Therapeutics, Inc., a San Diego-based company focused on lipidomics-based therapeutics that will use the funding from the award, along with matching third-party partner funds, to advance its lead product candidate ASONEP™, a potentially first-in-class anti-cancer agent which binds to and inhibits the bioactive lipid Sphingosine-1-Phosphate (S1P), a multifunctional mediator that can become dysfunctional and contribute directly to the pathophysiology of cancer.
- OptoSonics, a North Carolina-based company focused on developing molecular imaging instrumentation used in the fields of molecular biology, oncology, drug discovery, diagnostics, and therapeutic medicine. OptoSonics will utilize this funding, along with matching third-party partner funds, to advance a photoacoustic computed-tomography (PCT) scanner for conducting preclinical molecular imaging.
Read about more NCI SBIR & STTR funding opportunities.
Click here to view videos from the NCI SBIR & STTR Programs about how to apply for funding opportunities.
